Destination Amyotrophic Lateral Sclerosis.
early signs
gene-environment interaction
motor neurons
neurodegeneration
neuromuscular disease
pathophysiology
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
08
2020
accepted:
02
03
2021
entrez:
15
4
2021
pubmed:
16
4
2021
medline:
16
4
2021
Statut:
epublish
Résumé
Amyotrophic Lateral Sclerosis (ALS) is a prototypical neurodegenerative disease characterized by progressive degeneration of motor neurons both in the brain and spinal cord. The constantly evolving nature of ALS represents a fundamental dimension of individual differences that underlie this disorder, yet it involves multiple levels of functional entities that alternate in different directions and finally converge functionally to define ALS disease progression. ALS may start from a single entity and gradually becomes multifactorial. However, the functional convergence of these diverse entities in eventually defining ALS progression is poorly understood. Various hypotheses have been proposed without any consensus between the for-and-against schools of thought. The present review aims to capture explanatory hierarchy both in terms of hypotheses and mechanisms to provide better insights on how they functionally connect. We can then integrate them within a common functional frame of reference for a better understanding of ALS and defining future treatments and possible therapeutic strategies. Here, we provide a philosophical understanding of how early leads are crucial to understanding the endpoints in ALS, because invariably, all early symptomatic leads are underpinned by neurodegeneration at the cellular, molecular and genomic levels. Consolidation of these ideas could be applied to other neurodegenerative diseases (NDs) and guide further critical thinking to unveil their roadmap of destination ALS.
Identifiants
pubmed: 33854469
doi: 10.3389/fneur.2021.596006
pmc: PMC8039771
doi:
Types de publication
Journal Article
Langues
eng
Pagination
596006Informations de copyright
Copyright © 2021 Keon, Musrie, Dinger, Brennan, Santos and Saksena.
Déclaration de conflit d'intérêts
MK, BM, and SB are employed by GenieUs Genomics Pty Ltd. NS is employed by Epigenes Australia Pty Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that the entire funding for this review was provided by the GeneiUs, Darlinghurst NSW, Sydney, Australia.
Références
Neurology. 2012 Oct 16;79(16):1732-9
pubmed: 23071166
Nat Rev Dis Primers. 2017 Oct 20;3:17085
pubmed: 29052611
Amyotroph Lateral Scler. 2012 Jun;13(4):351-6
pubmed: 22424129
Proc Natl Acad Sci U S A. 2017 May 16;114(20):E3935-E3943
pubmed: 28396410
Acta Neurol Scand. 1992 Feb;85(2):81-9
pubmed: 1574993
Brain Res. 2012 Jun 26;1462:100-11
pubmed: 22405728
Lancet Neurol. 2017 Jul;16(7):505-512
pubmed: 28522181
Science. 2006 Oct 6;314(5796):130-3
pubmed: 17023659
J Neurol Neurosurg Psychiatry. 2011 Jul;82(7):740-6
pubmed: 21402743
N Engl J Med. 1992 May 28;326(22):1464-8
pubmed: 1349424
Neuron. 2012 Mar 22;73(6):1216-27
pubmed: 22445348
JAMA Neurol. 2015 Mar;72(3):316-24
pubmed: 25580592
PLoS One. 2008 Aug 06;3(8):e2849
pubmed: 18682740
Ann Neurosci. 2018 Dec;25(4):261-267
pubmed: 31000966
Neural Regen Res. 2013 Jul 25;8(21):2003-14
pubmed: 25206509
Nat Rev Neurol. 2013 Nov;9(11):617-28
pubmed: 24126629
JAMA Neurol. 2013 Dec;70(12):1562-5
pubmed: 24145758
J Neurol Neurosurg Psychiatry. 2003 May;74(5):683-6
pubmed: 12700323
Neuroscience. 2010 Sep 15;169(4):1621-9
pubmed: 20600671
Mol Neurodegener. 2020 Jun 8;15(1):34
pubmed: 32513219
Free Radic Biol Med. 2013 Dec;65:509-527
pubmed: 23797033
Neurol Clin. 2015 Nov;33(4):855-76
pubmed: 26515626
Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec;15(7-8):610-7
pubmed: 25286015
Nucleic Acids Res. 2005 Jan 1;33(Database issue):D428-32
pubmed: 15608231
Transl Neurodegener. 2017 Jun 16;6:15
pubmed: 28638596
Int J Mol Sci. 2017 Oct 03;18(10):
pubmed: 28972545
J Neurol Sci. 2016 Sep 15;368:352-8
pubmed: 27538664
J Neurochem. 1997 Nov;69(5):1945-53
pubmed: 9349539
Ann Gastroenterol. 2015 Apr-Jun;28(2):203-209
pubmed: 25830558
Neurosci J. 2019 Jul 10;2019:2537698
pubmed: 31380411
J Exp Neurosci. 2016 Sep 04;10(Suppl 1):23-48
pubmed: 27625575
Neurology. 2018 Aug 14;91(7):e635-e642
pubmed: 30045958
Nat Rev Neurol. 2013 Dec;9(12):708-14
pubmed: 24217521
Neurology. 2009 Sep 8;73(10):805-11
pubmed: 19738176
Front Endocrinol (Lausanne). 2020 Jan 31;11:25
pubmed: 32082260
Curr Mol Med. 2011 Apr;11(3):246-54
pubmed: 21375489
J Neurol Neurosurg Psychiatry. 2015 Jun;86(6):667-73
pubmed: 25644224
PLoS One. 2011;6(5):e19987
pubmed: 21625445
J Neurosci. 2014 Nov 19;34(47):15587-600
pubmed: 25411487
Lancet Neurol. 2014 Nov;13(11):1108-1113
pubmed: 25300936
J Neurosci. 2015 Jan 14;35(2):688-706
pubmed: 25589763
Int J Mol Sci. 2020 May 14;21(10):
pubmed: 32422969
Annu Rev Neurosci. 2013 Jul 8;36:243-70
pubmed: 23701460
J Anat. 2014 Jan;224(1):45-51
pubmed: 24010870
Nucleic Acids Res. 2011 Jan;39(Database issue):D691-7
pubmed: 21067998
Br J Cancer. 1954 Mar;8(1):1-12
pubmed: 13172380
Virol J. 2013 May 31;10:172
pubmed: 23724961
J Clin Med. 2020 Jan 18;9(1):
pubmed: 31963681
Acta Ophthalmol Scand. 2007 Dec;85(8):897-901
pubmed: 17680840
Front Neurol. 2019 Feb 21;10:143
pubmed: 30846968
Nature. 2019 Aug;572(7770):474-480
pubmed: 31330533
Front Mol Neurosci. 2019 Feb 14;12:25
pubmed: 30837838
J Neurogastroenterol Motil. 2019 Jan 31;25(1):48-60
pubmed: 30646475
Exp Neurol. 2004 Feb;185(2):232-40
pubmed: 14736504
Ann Neurol. 1987 Nov;22(5):580-6
pubmed: 3501273
Nucleic Acids Res. 2016 Jan 4;44(D1):D481-7
pubmed: 26656494
Lancet Neurol. 2012 Mar;11(3):232-40
pubmed: 22305801
J Neuroimmunol. 2009 May 29;210(1-2):73-9
pubmed: 19307024
Curr Opin Rheumatol. 2003 Nov;15(6):730-6
pubmed: 14569202
Arch Ital Biol. 2017 Dec 1;155(4):131-141
pubmed: 29405030
Neuron. 2018 Mar 21;97(6):1268-1283.e6
pubmed: 29566793
Orphanet J Rare Dis. 2009 Feb 03;4:3
pubmed: 19192301
Front Genet. 2019 Jan 22;9:712
pubmed: 30723494
Neuron. 2017 Nov 1;96(3):651-666
pubmed: 29096078
Toxicon. 2011 Apr;57(5):803-10
pubmed: 21334358
Acta Neurol Scand. 1985 Jun;71(6):480-4
pubmed: 4024859
Amyotroph Lateral Scler Frontotemporal Degener. 2019 Nov;20(7-8):532-537
pubmed: 31284763
Hum Mol Genet. 2017 Oct 1;26(R2):R91-R104
pubmed: 28977445
PLoS One. 2014 Dec 26;9(12):e114569
pubmed: 25541992
Neurology. 2013 Apr 23;80(17):1590-7
pubmed: 23553481
Nat Rev Neurosci. 2006 Apr;7(4):278-94
pubmed: 16552414
BMC Med. 2020 Jun 17;18(1):153
pubmed: 32546239
Neurobiol Dis. 2017 Sep;105:283-299
pubmed: 28235672
Amyotroph Lateral Scler. 2009;10 Suppl 2:74-8
pubmed: 19929737
Nature. 2016 Nov 10;539(7628):197-206
pubmed: 27830784
Trends Neurosci. 2020 May;43(5):274-284
pubmed: 32353332
Muscle Nerve. 2014 Apr;49(4):469-77
pubmed: 24273101
Nat Neurosci. 2014 Jan;17(1):17-23
pubmed: 24369373
Free Radic Biol Med. 2010 Mar 1;48(5):629-41
pubmed: 19969067
J Neurosci. 2015 Jan 14;35(2):643-7
pubmed: 25589758
Mol Cells. 2018 Sep 30;41(9):818-829
pubmed: 30157547
Med Hypotheses. 2019 Nov;132:109369
pubmed: 31442918
J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1232-8
pubmed: 24648037
CNS Neurol Disord Drug Targets. 2010 Jul;9(3):305-13
pubmed: 20406180